{"filings":[{"id":1968237,"accession_number":"0001384101-26-000042","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2026-07-30T20:18:32+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q2 revenue up 15% to $150.3M; launches Prosigna and TrueMRD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $150.3M (+15% YoY); testing revenue $145.7M (+19%); Decipher +20%, Afirma +18%.","GAAP net income $25.5M (17% of revenue); adjusted EBITDA $44.0M (29.2% of revenue).","Launched Prosigna LDT for early-stage HR+ breast cancer and TrueMRD for MIBC; secured Medicare coverage for TrueMRD.","Cash from ops $45.8M; cash & investments $485.2M as of June 30, 2026.","Total testing volume up 14% to 48,389 tests; Decipher tests +17%, Afirma +10%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1001037,"accession_number":"0001384101-26-000038","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2026-06-11T20:32:47+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Veracyte stockholders approve 3.5M share increase to 2023 equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected with strong support; votes ranged from 67.9M to 73.0M for.","Ratification of Ernst & Young as auditor for 2026 passed with 75.5M votes for, 0.4M against.","Non-binding say-on-pay proposal approved: 71.3M for, 1.9M against, 2.7M broker non-votes.","2023 Equity Plan amendment approved: 52.1M for, 21.1M against, 2.7M broker non-votes.","Plan now reserved 16.3M total shares; amendment added 3.5M shares for future equity grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92542,"accession_number":"0001384101-26-000029","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q1 2026 revenue $139.1M (+21% YoY); GAAP net income $28.7M, adj. EBITDA $42.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $139.1M (+21% YoY); testing revenue $135.1M (+26% YoY).","GAAP net income $28.7M (20.6% of revenue); adjusted EBITDA $42.8M (30.8% of revenue).","Decipher revenue $86.5M (+30%); Afirma revenue $46.4M (+21%).","Testing volume 45,248 (+19%); Decipher tests ~28,000 (+24%), Afirma ~17,200 (+12%).","Cash from operations $35.2M; cash & investments $439.1M; added Haas as CDTO and Ward as CHRO."],"consensus_eps_estimate":null,"consensus_eps_actual":0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":139071000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103449,"accession_number":"0001384101-26-000012","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Veracyte appoints Kevin Haas as Chief Development & Technology Officer, effective March 24, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kevin Haas, formerly CTO of Myriad Genetics (NASDAQ: MYGN), joins as Chief Development and Technology Officer.","Compensation includes $500,000 base salary, 55% target bonus, RSUs and PSUs each valued at $1.5 million.","RSU vests over four years; PSU vests upon achievement of performance objectives set by Compensation Committee.","No family relationships or material transactions with the company or its other officers disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103448,"accession_number":"0001384101-26-000008","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q4 revenue $140.6M (+19% YoY); GAAP net income $41.1M, generates $52.6M operating cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $140.6M (+19% YoY); testing revenue $135.8M (+21%); total volume 48,019 tests (+16%).","Decipher revenue $85.6M (+27%); Afirma revenue $47.9M (+16%); strong double-digit growth in both segments.","GAAP net income $41.1M (29.3% margin); adjusted EBITDA $42.3M (30.1% margin); $52.6M operating cash flow.","Full-year 2025 revenue $517.1M (+16% YoY); GAAP net income $66.4M; adjusted EBITDA $142.5M; operating cash $136.3M.","Ended 2025 with $412.9M cash; plans to launch Prosigna LDT and TrueMRD test in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":517145000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103447,"accession_number":"0001384101-26-000002","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte prelim Q4 rev $138M-$140M (+16-18% YoY); guides FY26 rev $570M-$582M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 total revenue $515M-$517M (+16% YoY); testing revenue $491M-$493M.","Decipher volume +27% to ~102K; Afirma volume +11% to ~67.7K in FY2025.","Prelim FY2025 adj EBITDA margin >25%; FY2026 margin guided at 25%.","FY2026 total revenue guidance 10-13% growth ($570M-$582M); testing rev +14-16% ($559M-$569M excl. new tests).","CEO cites upcoming US launch of Prosigna and TrueMRD as growth catalysts."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":517145000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119703,"accession_number":"0001384101-25-000128","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q3 revenue up 14% to $131.9M, raises FY guidance; adjusted EBITDA margin 30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $131.9M (+14% YoY); testing rev $127.8M (+17%); GAAP net income $19.1M.","Decipher revenue $82.2M (+26%); Afirma $43.2M (+7%); total testing volume +19% to 43,679.","Adjusted EBITDA $39.7M (30% margin); cash from ops $44.8M; cash & equivalents $366.4M.","Raised FY2025 total revenue guidance to $506-510M; testing rev guidance $484-487M (+16%).","Completed enrollment of Percepta Nasal Swab NIGHTINGALE trial; upcoming TrueMRD and Prosigna LDT launches."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":376509000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136277,"accession_number":"0001384101-25-000106","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q2 revenue $130.2M (+14% YoY); raises testing revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue of $130.2M (+14% YoY); testing revenue of $122.3M (+14%).","Decipher revenue $76.3M (+24%), volume ~25,500 (+28%); Afirma revenue $43.4M (+5%).","GAAP net loss $1.0M includes $20.5M impairment; adj. EBITDA $35.8M (27.5% of revenue).","Cash from operations $33.6M; cash & investments $320.7M at quarter end.","Raises FY2025 testing revenue guidance to $477-483M (14-15% growth); FY total revenue $496-504M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":244637000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153379,"accession_number":"0001384101-25-000083","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"VCYT shareholders approve 2.5M share equity plan increase, elect all directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2023 Plan Amendment to increase shares reserved by 2,500,000 (For: 50.6M, Against: 19.1M).","All seven director nominees elected; Muna Bhanji received 14% against votes (9.6M against, 545K abstain).","Advisory vote on executive compensation approved with 97.3% support (67.8M For, 1.8M Against).","Board adopts annual Say-on-Pay frequency based on advisory vote (66.8M for one year).","Ernst & Young ratified as independent auditor for 2025 with 99.7% approval (72.2M For)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153378,"accession_number":"0001384101-25-000058","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q1 2025 revenue $114.5M (+18% YoY); net income $7.0M, Decipher revenue up 33%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $114.5M (+18% YoY); testing revenue $107.3M (+19%); total test volume 40,655 (+22%).","Decipher revenue $66.6M (+33%); Afirma revenue $38.3M (+6%); Decipher volume ~22,600 (+37%).","Net income $7.0M (6.2% of revenue); adjusted EBITDA $24.7M (21.6% of revenue).","Launched limited access to Decipher for metastatic prostate cancer, expanding addressable population.","Cash and short-term investments $287.4M; generated $5.4M cash from ops."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":114473000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172141,"accession_number":"0001384101-25-000010","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q4 revenue $118.6M (+21%), net income $5.1M vs. loss a year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $118.6M (+21%), testing revenue $112.2M (+24%), testing volume +25% to 39,107 tests.","Q4 net income $5.1M vs. net loss in Q4 2023; adjusted EBITDA $26.1M (22.0% margin), up 76%.","Full-year 2024 revenue $445.8M (+23%), net income $24.1M vs. 2023 loss; adj. EBITDA $91.9M (20.6%).","Decipher revenue +44% in Q4, volume +45% to >22,400 tests; Afirma revenue +4%, volume +8%.","Cash from operations $75.1M in 2024; ended with $289.4M cash & short-term investments."],"consensus_eps_estimate":null,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":445764000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189109,"accession_number":"0001384101-24-000160","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q3 revenue $115.9M (+29% YoY), net income $15.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Testing revenue $109.5M (+34%); total testing volume 36,792 (+24%); total tests 39,032 (+20%).","Decipher revenue +48%, volume +36% (21,250 tests); Afirma revenue +19%, volume +12% (15,100 tests).","GAAP net income $15.2M; adjusted EBITDA $27.3M (24% margin); operating cash flow $30.0M.","Presented Decipher Prostate clinical data from STAMPEDE (ESMO) and VANDAAM (ASTRO); added two directors and SVP of Operations."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":327132000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205597,"accession_number":"0001384101-24-000133","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Veracyte appoints Tom Miller, Ph.D. and Brent Shafer to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointments effective September 3, 2024; terms until 2025 annual meeting or successor.","Miller joins Regulatory and Compliance Committee; Shafer joins Compensation Committee.","Both eligible for standard non-employee director compensation; no related-party transactions.","No family relationships with existing directors or officers; standard indemnity agreements signed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205596,"accession_number":"0001384101-24-000116","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q2 revenue $114.4M (+27% YoY); net income $5.7M; record test volumes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $114.4M (+27% YoY); testing revenue +31%; test volume 39,023 (+23%).","Net income $5.7M; adjusted EBITDA $24.0M (21% of revenue); generated $26.7M cash.","Record Decipher Prostate volume ~19,900 (NCCN guideline boost); Afirma volume ~15,700 (new Medicare coverage for Bethesda V).","Cash and cash equivalents $235.9M; three Decipher studies published including SEER-linked analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":211272000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222537,"accession_number":"0001384101-24-000093","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Veracyte stockholders approve 5M share increase under 2023 equity plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Annual meeting held June 12, 2024; all four proposals passed.","Stockholders approved amendment to 2023 Equity Incentive Plan adding 5,000,000 shares (45,241,870 For, 22,565,308 Against).","Directors Muna Bhanji (61,780,051 votes) and Marc Stapley (67,220,523) elected to one-year terms.","Ratified Ernst & Young as independent auditor for FY2024 (70,832,239 For).","Non-binding say-on-pay approved (64,610,097 For)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222536,"accession_number":"0001384101-24-000064","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q1 revenue $96.8M (+17%), testing revenue +25%, net loss narrows 77%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $96.8M (up 17% YoY); testing revenue $90.3M (up 25%) led by Decipher Prostate and Afirma.","Net loss improved 77% to $1.9M ($0.02 per share) from $8.3M loss in Q1 2023.","Non-GAAP gross margin held at 68%; non-GAAP op expenses grew 6% to $61.6M.","Decipher Prostate received highest NCCN rating; contracted with large commercial payer covering ~30M members.","Completed C2i Genomics acquisition for MRD testing; initiated bladder cancer MRD test; cash $209.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":96844000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222535,"accession_number":"0001384101-24-000051","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K/A","filed_at":"2024-04-17T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Veracyte completes C2i acquisition for up to $95M stock; C2i had $36M loss, $78.6M debt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Feb 5, 2024; total consideration up to $95M in Veracyte common stock.","C2i 2023 revenue $456k, net loss $36.0M, R&D expense $17.9M, operating loss $21.9M.","C2i had $78.6M in convertible promissory notes, $18.8M cash, $76.1M accumulated deficit as of Dec 31, 2023.","Veracyte files audited C2i financials and unaudited pro forma combined statements to satisfy SEC requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242060,"accession_number":"0001193125-24-075385","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Veracyte registers 1,016,965 shares for resale relating to C2i Genomics acquisition","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed prospectus supplement to register 1,016,965 shares of common stock for resale.","Shares were issued as part of the consideration for the February 5, 2024 acquisition of C2i Genomics.","Legal opinion from Fenwick & West LLP regarding the legality of the registered shares filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242059,"accession_number":"0001193125-24-053689","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Veracyte registers 1.68M shares for resale related to C2i Genomics acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to register up to 1,681,384 shares of common stock for resale.","Shares were issued in connection with the acquisition of C2i Genomics, Inc. on Feb 5, 2024.","Includes opinion of counsel (Fenwick & West) on legality of the shares.","This is a procedural step; no new financial or operational information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242058,"accession_number":"0001384101-24-000013","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q4 revenue $98.2M (+22% YoY); full-year $361.1M (+22%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $98.2M, up 22% YoY; testing revenue $90.4M (+29%).","Full-year 2023 revenue $361.1M, up 22%; total test volume 126,977 (+24%).","Net loss $28.3M ($0.39/share) includes $32M impairment; non-GAAP gross margin 70%.","Generated $44M cash from operations in FY2023; cash on hand $216M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":361051000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242057,"accession_number":"0001384101-24-000007","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"John L. Bishop to retire from Veracyte board at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John L. Bishop informed the board he will retire and not stand for reelection at the 2024 annual meeting.","He will continue serving until the end of his term at the 2024 annual meeting.","Bishop has served on the board for ten years.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242056,"accession_number":"0001384101-24-000004","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.01","9.01","3.02"],"status":"ready","headline":"Veracyte completes $70M acquisition of C2i Genomics; milestone payments up to $25M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price of $70M paid to C2i Genomics securityholders, subject to customary adjustments.","Up to $25M in additional milestone payments payable in cash or stock over next two years.","Veracyte to issue up to 2,698,349 shares as stock consideration; cash in lieu for non-accredited investors.","SEC granted partial waiver from certain financial statement requirements under Rule 3-13.","Closing occurred on February 5, 2024; audited C2i financials to be filed within 71 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242055,"accession_number":"0001193125-24-003949","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Veracyte acquires C2i Genomics for $70M in stock; reports preliminary 2023 revenue up 21%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Q4 2023 revenue $95-96M (+18-20% YoY); full-year revenue $358-359M (+21%).","Total test volume ~34,000 in Q4 (+21%), ~127,000 full-year (+24%).","2024 revenue guidance 10-12% growth ($394-402M); cash >$215M at year-end.","Acquires C2i Genomics for $70M in Veracyte shares at close plus up to $25M milestone; expected close Q1 2024.","First MRD test in muscle-invasive bladder cancer, leveraging urology commercial channel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259457,"accession_number":"0001384101-23-000161","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q3 2023 revenue up 19% to $90.1M; net loss widens on $34.9M impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $90.1M, +19% YoY; testing revenue $82.0M, +27% YoY.","Net loss $29.6M ($0.41 per share) vs $8.7M loss a year ago; includes $34.9M impairment from nCounter license.","Total test volume 32,544, +23% YoY.","Non-GAAP gross margin 69% vs 66% prior year; generated $14.2M cash from ops, cash $202.5M.","Management cites strong demand for Decipher Prostate and Afirma tests driving growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":262852000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276729,"accession_number":"0001384101-23-000140","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Veracyte Q2 revenue $90.3M (+24% YoY); GM Urological Cancers Tina Nova resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $90.3M (+24% YoY); testing revenue $81.7M (+37%); test volume 31,809 (+28%).","Net loss $8.4M (-$0.12 EPS), improved 12% YoY; cash from ops $17M in Q2; cash $191M.","Biopharma revenue $4.6M (-55% YoY); product revenue $4.0M (+29%).","Tina Nova resigns as GM Urological Cancers (eff. Sept 3); advisor role $10k/month for 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":172744000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294532,"accession_number":"0001384101-23-000112","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Veracyte shareholders approve 2023 Equity Plan and board declassification; officer exculpation fails at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 2023 Equity Incentive Plan, reserving 5,306,156 shares for issuance.","Board declassification amendment adopted; directors will now stand for annual election.","Officer exculpation amendment under DGCL 102(b)(7) failed: 43.6M for, 21.2M against, 0.7M abstain.","Re-elected Class I directors Robert S. Epstein and Evan Jones to serve until 2026.","Ratified Ernst & Young as 2023 auditor; non-binding say-on-pay approved with 63.6M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294531,"accession_number":"0001384101-23-000065","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q1 beats: revenue $82.4M (+22%), net loss shrinks 44% to $8.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $82.4M (+22% YoY); testing revenue $72.4M (+29%); product revenue $3.9M (+31%).","Net loss improved 44% to $8.1M; diluted EPS -$0.11 from -$0.20.","Total test volume 28,788 (+24%); ended cash $177.9M near flat.","Non-GAAP gross margin 68% (vs 65%); operating expenses up 14% to $61.9M.","Enhanced Afirma test with TERT promoter testing; secured 4 new payer contracts."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":82422000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315125,"accession_number":"0001384101-23-000011","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q4 revenue $80.3M (+19% YoY); full-year $296.5M (+35%); net loss narrows 63%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $80.3M (up 19% YoY); testing revenue $70.3M (+32%); net loss $3.8M (improved 63%).","Full-year 2022 revenue $296.5M (+35%); net loss $36.6M (improved 52%); EPS -$0.51 (improved 54%).","Total test volume 28,001 in Q4 (+26% YoY) and 102,524 for full year (+30%).","Generated $9.7M cash from operations in Q4; ended year with $178.9M cash and investments.","Promoted Annie McGuire to General Counsel and Chief People Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":296536000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315124,"accession_number":"0001384101-23-000007","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Veracyte adopts amended bylaws for universal proxy rules and DGCL updates","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amended bylaws on Feb 9, 2023, effective immediately.","Adds requirements for stockholder nominees under SEC Rule 14a-19 universal proxy.","Enhances advance notice provisions: additional disclosures, nominee interview requirements, and proxy card color rule.","Conforms adjournment and electronic notice provisions to recent DGCL amendments.","Includes emergency bylaw and stockholder list publication provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333458,"accession_number":"0001384101-22-000162","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Veracyte's Global CSO/CMO Giulia Kennedy to depart Dec. 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kennedy will leave Veracyte effective Dec. 31, 2022; separation agreement signed.","Severance includes six months' salary and up to 24 months of COBRA coverage.","She will receive her 2022 annual performance bonus at the corporate achievement level.","Additional $100,000 cash payment in appreciation for her contributions as an early employee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333457,"accession_number":"0001384101-22-000137","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q3 revenue up 25% to $75.6M; net loss improves 38%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $75.6M (+25% YoY), test volume 26,374 (+26% YoY).","Net loss $8.7M improves 38% YoY; diluted EPS -$0.12 improves 40% YoY.","Non-GAAP gross margin 66% vs 64% prior year; operating cash flow $7.0M in Q3.","Decipher Prostate gets NCCN Level 1 evidence; commercial coverage expanded to 195M lives for Decipher, 230M for Afirma.","Ended Q3 with $170.1M cash; appointed Dr. Eliav Barr to board, John Leite as GM Pulmonology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":216239000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350971,"accession_number":"0001384101-22-000121","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Veracyte appoints Eliav Barr, M.D. to board of directors, effective August 9, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Barr appointed as Class III director with term expiring at 2025 annual meeting.","Also appointed to the Regulatory and Compliance Committee of the board.","Receives annual cash retainer of $40,000 plus $5,000 for committee service.","Initial restricted stock unit grant valued at $500,000, vesting over three years.","Enters standard indemnification agreement for non-executive directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350970,"accession_number":"0001384101-22-000105","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q2 revenue $72.9M (+32% YoY); net loss $9.5M, EPS -$0.13","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $72.9M, +32% YoY; testing $59.7M (+18%), biopharma $10.0M (vs $1.6M).","Test volume 24,904, +19% YoY; GAAP gross margin 59%, non-GAAP 66%.","Net loss $9.5M (+5% YoY), EPS -$0.13; non-GAAP op expenses $49.0M.","Cash and investments $164.0M at June 30; operating cash flow improved $29.4M YTD.","AUA/ASRO guideline now favorable for Decipher Prostate; multiple clinical data presentations at ASCO, ENDO, ESMO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":140647000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368180,"accession_number":"0001384101-22-000086","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Veracyte shareholders elect directors, ratify auditor, approve executive compensation at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Karin Eastham re-elected as Class III director: 52.2M for, 12.1M against, 190K abstain.","Jens Holstein re-elected as Class III director: 64.3M for, 120K against, 11.2K abstain.","Ratification of Ernst & Young as independent auditor for 2022 approved: 67.2M for, 61.6K against.","Advisory vote on named executive officer compensation approved: 59.1M for, 5.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368179,"accession_number":"0001384101-22-000068","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q1 revenue up 85% to $67.8M; net loss narrows 65%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $67.8M, +85% YoY; test volumes 23,245, +61% YoY.","Testing revenue $56.0M (+69%); Biopharma and other $8.8M (vs $0.6M); product revenue $3.0M (-3%).","GAAP net loss $14.5M, improved 65%; diluted EPS loss $0.20, improved 70%.","Non-GAAP gross margin 65%, roughly flat; cash $163.6M at quarter-end.","Business highlights: expanded Percepta data at ATS, three AUA abstracts, launch of Biopharma Atlas."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":67783000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387515,"accession_number":"0001384101-22-000026","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q4 2021 revenue $67.3M (+95% YoY); guides 2022 revenue $260-275M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $67.3M (+95% YoY); full-year 2021 revenue $219.5M (+87% YoY).","Net loss $10.5M in Q4 ($0.15 per share); full-year loss $75.6M ($1.11 per share).","Test volume grew to 22,300 in Q4 (+70% YoY); full-year volume 78,565 (+77% YoY).","2022 revenue guidance $260M-$275M, representing 18-25% YoY growth.","Completed acquisitions of Decipher Biosciences and HalioDx; launched Decipher Bladder test."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":219514000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387514,"accession_number":"0001384101-22-000015","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Veracyte appoints Jonathan Wygant as CAO; Beverly Alley to depart in June 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jonathan Wygant named VP & Chief Accounting Officer, effective March 1, 2022.","Wygant receives $350k base salary, 35% bonus target, 24k stock options, 12k RSUs.","Beverly Alley transitions to VP, Accounting through June 30, 2022, then departs.","Alley receives 3 months' salary and COBRA continuation upon separation.","Wygant previously served as corporate controller at Biosplice Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387513,"accession_number":"0001384101-22-000004","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2022-01-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Veracyte appoints Tina Nova as President of CLIA U.S. business","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tina S. Nova, Ph.D., appointed President of Veracyte's CLIA U.S. business effective January 6, 2022.","Dr. Nova previously served as General Manager, Thyroid and Urologic Cancers since March 2021.","She was on Veracyte's board from Nov 2015 to Feb 2021 and was CEO of Decipher before its acquisition.","Dr. Nova will enter into standard indemnification agreement; no family relationships or material transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405458,"accession_number":"0001384101-21-000173","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q3 2021 revenue $60.4M (+94% YoY); raises FY guidance to $210-218M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $60.4M, up 94% YoY; volume 20,972 tests (+79%).","Net loss $14.1M ($0.20 EPS) vs $4.1M loss Q3 2020; includes HalioDx costs.","Completed HalioDx acquisition for $321M; launched Percepta Nasal Swab and Decipher Bladder tests.","FY 2021 revenue guidance raised to $210-218M from $200-208M, implying 79-86% growth.","Cash $164M at quarter-end; operating cash used $1.4M incl. $3.9M acquisition expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":152178000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424496,"accession_number":"0001384101-21-000144","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Veracyte registers 3.35M shares for resale from HalioDx acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to register up to 3,347,493 shares of common stock for resale.","Shares were issued in connection with the HalioDx SAS acquisition that closed on August 2, 2021.","Opinion of counsel (Fenwick & West LLP) on legality of the registered shares attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424495,"accession_number":"0001384101-21-000141","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2021-08-03T23:59:59+00:00","items":["2.01","3.02"],"status":"ready","headline":"Veracyte completes €260M acquisition of HalioDx in cash and stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration €260M: ~€147M cash + ~€113M in Veracyte common stock.","Acquisition of HalioDx, a French immuno-oncology diagnostics company.","Closing on August 2, 2021, as previously announced June 1 and July 13.","Stock consideration issued as unregistered securities under Item 3.02."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424494,"accession_number":"0001384101-21-000138","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2021-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q2 revenue $55.1M (+166% YoY); raises 2021 guidance to $200-208M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $55.1M, up 166% YoY; net loss $9.0M ($0.13 per share) improved 18%.","Genomic test volume 20,856, up 215% YoY and 44% sequentially.","Raises FY2021 revenue guidance to $200-208M from $190-200M.","Received Medicare coverage for Decipher Bladder; signed managed care contract for Decipher Prostate (~20M members).","Planned HalioDx acquisition announced; new CFO, CBO, CIO appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":91808000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424493,"accession_number":"0001384101-21-000123","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2021-07-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Veracyte announces retirement of EVP and General Counsel James Erlinger effective July 31, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James H. Erlinger III, EVP, General Counsel and Secretary, retires effective July 31, 2021.","Severance: three months' salary and three months' COBRA continuation coverage in exchange for standard release of claims.","No replacement named in the filing; Marc Stapley remains CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424492,"accession_number":"0001384101-21-000120","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2021-07-13T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Veracyte signs definitive agreement to acquire HalioDx for up to €113M in stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Entered into Securities Purchase and Contribution Agreement on July 13, 2021.","Consideration includes up to €113M in Veracyte common stock, with option to substitute cash.","Closing subject to customary conditions, including French foreign investment authorization.","Stock to be issued in private placement exempt from registration under Section 4(a)(2) and/or Regulation S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424491,"accession_number":"0001384101-21-000118","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2021-07-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Veracyte appoints Rebecca Chambers as CFO effective July 19, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rebecca Chambers, 43, appointed CFO effective July 19, 2021; previously CFO of Outset Medical.","Jane Alley resigns as acting CFO (same date) but remains VP, Corporate Controller and PAO.","Chambers gets $450K salary, $100K sign-on bonus, 67,000 stock options, 34,000 RSUs, and up to 13,600 performance-based RSUs.","Severance: 50% base salary for non-CIC termination; 150% plus full equity vesting for change-of-control termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}